A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
复制标题
DOI：
10.1038/bjc.2013.380
复制
发表时间：
2013-08-20
影响因子：
8.8
通讯作者：
Hotte, S. J.
中科院分区：
文献类型：
--
作者：
Sahebjam, S.;Bedard, P. L.;Castonguay, V.;Chen, Z.;Reedijk, M.;Liu, G.;Cohen, B.;Zhang, W-J;Clarke, B.;Zhang, T.;Kamel-Reid, S.;Chen, H.;Ivy, S. P.;Razak, A. R. A.;Oza, A. M.;Chen, E. X.;Hirte, H. W.;McGarrity, A.;Wang, L.;Siu, L. L.;Hotte, S. J.
The Notch signalling pathway has been implicated in tumour initiation, progression, angiogenesis and development of resistance to vascular endothelial growth factor (VEGF) targeting, providing a rationale for the combination of RO4929097, a γ-secretase inhibitor, and cediranib, a VEGF receptor tyrosine kinase inhibitor. Patients received escalating doses of RO4929097 (on a 3 days-on and 4 days-off schedule) in combination with cediranib (once daily). Cycle 1 was 42 days long with RO4929097 given alone for the first 3 weeks followed by the co-administration of both RO4929097 and cediranib starting from day 22. Cycle 2 and onwards were 21 days long. Soluble markers of angiogenesis were measured in plasma samples. Archival tumour specimens were assessed for expression of three different components of Notch signalling pathway and genotyping. In total, 20 patients were treated in three dose levels (DLs). The recommended phase II dose was defined as 20 mg for RO4929097 on 3 days-on and 4 days-off schedule and 30 mg daily for cediranib. The most frequent treatment-related adverse events (AEs) were diarrhoea, hypertension, fatigue and nausea. Eleven patients had a best response of stable disease and one patient achieved partial response. We did not detect any correlation between tested biomarkers of angiogenesis or the Notch pathway and treatment effect. There was no correlation between mutational status and time to treatment failure. RO4929097 in combination with cediranib is generally well tolerated at the DLs tested. Preliminary evidence of antitumour efficacy with prolonged disease stabilisation in some patients with progressive malignancies warrants further clinical investigation of this treatment strategy.
登录
查看更多内容
影响因子：
11.5
作者：
Patel, Nilay S.;Dobbie, Michael S.;Harris, Adrian L.
通讯作者：
Harris, Adrian L.
影响因子：
3.7
作者：
Lin, Jen-Tsun;Chen, Mu-Kuan;Chang, Pey-Jium
通讯作者：
Chang, Pey-Jium
影响因子：
11.5
作者：
Wu, Jianmei;LoRusso, Patricia M.;Li, Jing
通讯作者：
Li, Jing
影响因子：
45.3
作者：
Goss, Glenwood D.;Arnold, Andrew;Seymour, Lesley
通讯作者：
Seymour, Lesley
影响因子：
8.4
作者：
Mulders, Peter;Hawkins, Robert;Gore, Martin E.
通讯作者：
Gore, Martin E.